

Date: 21st November 2023

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Sub: Un-Audited Standalone and Consolidated Financial Results for half year ended 30th September 2023

In pursuant to Regulations 30 & 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and in continuation to our submission on 14th November 2023 and requirement of NSE, Please find attached Un-Audited Standalone & Consolidated Financial Results for the half year ended on 30th September 2023 along with Report thereon in machine readable format

We would request you to take the above intimation on records.

For, **Vaidya Sane Ayurved Laboratories Limited**

Abhishek Deshpande
Company Secretary & Compliance Officer

VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:

Fl.5 1047, Shriram Bhawan, Shukrawar Peth,
Pune- 411002, Maharashtra India.
CIN No : L73100PN1999PLC013509

Corporate Office Address:

Ishan Bldg. No. 2, 701, 7th Floor, Gokhale Road, Naupada,
Thane (W)-400 602. Tel: +91 022-41235315/16
www.madhavbaug.org



A. A. MOHARE & CO.
CHARTERED ACCOUNTANTS

1/3, Shree Vivekanand CHS Ltd.,
Guru Mandir Road, Saraswat Colony,
Dombivli (East) 421 201.
M : 9223 543 842 / LL : 0251 – 2473000
Email : amit@aamco.in

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTORIES LIMITED


To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Vaidya Sane Ayurved Laboratories Limited ("the Company"), for six months ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as Amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. A. Mohare & Co.

Chartered Accountants (FRN 114152W)


Amit Mohare


Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPI5671



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Balance sheet as at 30-Sep-2023

(Rupees in Lakhs)

	Unaudited As at 30-Sep-23	Unaudited As at 30-Sep-22	Audited As at 31-Mar-23
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1,051.35	1,051.35	1,051.35
Reserves and surplus	3,045.09	2,838.02	3,029.63
Money received against share warrants	1,343.13	-	-
	5,439.57	3,889.37	4,080.98
Non-current liabilities			
Deferred tax liabilities (net)	6.26	4.66	4.52
Other long-term liabilities	-	89.11	-
Long-term provisions	185.07	198.02	155.32
	191.33	291.79	159.84
Current liabilities			
Short-term borrowings	401.48	38.55	13.40
Trade payables	-	-	159.65
Total outstanding dues of micro enterprises and	-	-	736.29
Total outstanding dues of creditors other than	648.71	470.66	329.59
Other current liabilities	281.88	299.30	48.13
Short-term provisions	-	183.65	-
	1,332.07	992.16	1,287.06
Total	6,962.97	5,173.32	5,527.88
ASSETS			
Non-current assets			
Property, Plant and Equipment			
Tangible assets	1,818.95	1,646.38	1,843.43
Intangible assets	236.88	123.81	251.34
Capital work-in-progress	236.41	137.48	167.21
Long-term loans and advances	407.91	291.54	278.24
Non-current Investment	991.79	9.02	105.36
	3,691.94	2,208.23	2,645.58
Current assets			
Current investments	369.78	-	1,379.51
Inventories	257.04	154.47	341.38
Trade receivables	669.62	399.34	646.40
Cash and cash equivalents	1,479.95	1,967.51	175.15
Short-term loans and advances	494.64	364.64	339.86
Other current assets	-	79.13	-
	3,271.03	2,965.09	2,882.30
Total	6,962.97	5,173.32	5,527.88

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mahore


Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPI5671


For Vaidya Sane Ayurved Laboratories Limited
Rohit Sane

Chairman & Managing Director

DIN: 00679851

Place : Thane

Date : 14/11/2023



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Statement of profit and loss for the Half year ended September 30, 2023

Particulars	For the year ended September 30, 2023 Unaudited	For the year ended September 30, 2022 Unaudited	For the year ended March 31, 2023 Audited
Revenue			
Revenue from operations	5007.01	4,552.73	9,902.54
Other income	47.13	82.51	136.09
Total revenue	5054.14	4,635.23	10,038.63
Expenses			
Purchases of stock-in-trade	1595.22	1,306.45	2,762.28
Employee benefit expenses	1273.56	1,071.63	2,181.00
Finance costs	16.05	11.30	18.75
Depreciation and amortisation expense	154.59	115.53	259.79
Other expenses	1959.35	1,729.99	4,125.77
Total expenses	4,998.77	4,234.90	9,347.59
Profit / (loss) before prior period adjustments & tax.	55.37	400.33	691.04
Prior period adjustments	-	-	-
Profit / (loss) before extraordinary items and tax	55.37	400.33	691.04
Extraordinary items	-	-	-
Profit / (loss) before tax	55.37	400.33	691.04
Tax expense			
Current tax	11.9	99.30	172.26
Deferred tax (expense)/income	1.73	-0.08	-
Profit for the year	41.74	301.11	518.78
Earnings per equity share			
[Nominal value per share Rs. 10 (PY. 2022-23 - Rs.10)]			
Basic	0.40	2.86	4.94
Diluted	0.33	2.86	4.94

Notes :

- 1) The above financial results for the half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th Nov, 2023
- 2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid un-audited financial results for the half year ended 30th SEP 2023, which were also approved by the Audit Committee and Board at their meeting held on Tuesday, 14th Nov, 2023.
- 3) The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- 4) As per MCA Notification Dated 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category. It has not adapted IND-AS for preparation of financial results.
- 5) The company has issued and allotted 27,71,200 equity share having face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below,

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	1,600	0.00
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1972.98	0.00

As per our report on even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mohare

Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPI5671

For Vaidya Sane Ayurved Laboratories Limited**Rohit Sane**

Chairman & Managing Director

DIN: 00679851

Place : Thane

Date : 14/11/2023

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Standalone Cash flow statement for the period ended 30-Sep-2023



(Rupees in Lakhs)

	Unaudited	Unaudited	Audited
	For the half year ended 30-Sep-2023	For the half year ended 30-Sep-2022	For the half year ended 31-Mar-23
Cash flows from operating activities			
Profit before tax	55.37	132.72	691.04
Adjustments to reconcile net profit to net cash and cash			
Depreciation and amortisation expense	154.59	117.45	259.79
Finance Cost	16.05	10.88	18.75
Rent Income	(21.16)	-	(46.55)
Excess provision written back	(7.37)	-	(2.04)
Interest income on bank deposits	(16.33)	(0.10)	(87.27)
Dividend Income	(0.04)	-	(0.05)
	181.11	260.95	833.67
Change in operating assets and liabilities			
(Increase)/Decrease in inventory	84.34	32.72	(191.32)
(Increase)/Decrease in accounts receivable	(23.22)	(3.88)	(291.88)
(Increase)/Decrease in other current assets	-	0.66	-
Decrease/(Increase) in long term and short term advances	(255.18)	1.91	(335.02)
(Decrease)/Increase in accounts payable	(239.86)	(124.92)	161.45
(Decrease)/Increase in other current liabilities	(47.71)	(134.54)	32.27
(Decrease)/Increase in Long-term and Short-term provisions	(18.38)	44.74	10.16
Cash flow from operations	(318.90)	77.64	219.33
Direct taxes paid	(41.17)	(17.25)	(262.26)
Net cash flow from operating activities	(360.07)	60.39	(42.93)
Cash flows from investing activities			
Purchase of tangible/intangible assets	(184.85)	(76.61)	(698)
Purchase of current investments in shares	(899.18)	1.00	(105)
Dividend Income	0.04	-	0.05
Rent Income	21.16	-	46.55
Proceeds from maturity of fixed deposit	1,022.49	-	769.35
Interest received	16.33	-	87.27
Net cash used in investing activities	(24.01)	(75.61)	99.95
Cash flows from financing activities			
Money received against share warrants	1,343.13	-	-
Right Issue	-	76.72	-
Share Premium received	-	1,910.81	-
As required under Regulation 33 of SEBI (LODR) Regulations 2015	-	277.12	-
Short Term Loan Repayment	388.08	4.70	(92.93)
Interest paid	(16.05)	(20.18)	(18.75)
Interest Received	-	14.69	-
Dividend Paid	(26.28)	-	(26.28)
Cash flows from financing activities	1,688.88	2,263.86	(137.96)
Net (decrease)/ increase in cash and cash equivalents	1,304.80	2,248.64	(80.94)
Cash and cash equivalents at the beginning of the year	175.15	90.48	256.09
Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-	-
Cash and cash equivalents at the end of the year	1,479.95	2,339.12	175.15
Cash and cash equivalents comprise of			
Cash on hand	21.35	28.40	17.94
Balances with banks in current accounts	1,458.60	227.69	157.21
Total	1,479.95	256.09	175.15

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mahore
Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPI5671

For Vaidya Sane Ayurved Laboratories Limited


Rohit Sane
Chairman & Managing Director
DIN: 00679851
Place : Thane
Date : 14/11/2023





INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTORIES LIMITED

To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Vaidya Sane Ayurved Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax for six months ended September 30, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Parent and the following entities:

List of Subsidiaries:


1. Joint Healing Services Private Limited
2. F- Health Accelerators Private Limited
3. Dynamic Remedies Private Limited
4. UV Ayurgen Pharma Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review unaudited interim financial result of 4 subsidiaries included in the unaudited consolidated financial results, whose unaudited interim financial result reflect total assets of Rs. 68.81Crores as at September 30, 2023, total revenue of Rs. 51.73Crores for six month ended September 30,2023 respectively, total net profit after tax of Rs. 1.17Crores for six months ended September 30,2023 respectively and net cash inflow of Rs. 13.30Crores for the six months ended September 30, 2023, as considered in the Statement. These unaudited interim financial results have been reviewed by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, the procedures performed by us stated in paragraph 3 above.
7. Our conclusion on the Statement is not modified in respect of the above matter.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)



Amit Mohare

Partner

Membership No. 148601

Place : Thane

Date : 14.11.2023

UDIN : 23148601BGWJPH9648



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Consolidated Balancesheet as at 30-Sep-2023

(Rupees in lakhs)

	Unaudited As at 30-Sep-23	Unaudited As at 30-Sep-22	Audited As at 30-Mar-23
EQUITY AND LIABILITIES			
<i>Shareholders' funds</i>			
Share capital	1,051.35	1,051.35	1,051.35
Reserves and surplus	3,085.54	2,810.51	2,993.92
Money received against share warrants	1,343.13	-	-
	5,480.02	3,861.86	4,045.27
Minority Interest	-	-	0.16
	5,480.02	3,861.86	4,045.43
<i>Non-current liabilities</i>			
Long-term borrowings	-	-	-
Deferred tax liabilities (net)	-	4.66	-
Other long-term liabilities	-	89.12	-
Long-term provisions	191.90	198.02	155.32
	191.90	291.80	155.32
<i>Current liabilities</i>			
Short-term borrowings	401.48	38.55	13.40
Trade payables	-	-	159.65
Total outstanding dues of micro enterprises and small enterprises; and	-	-	736.84
Total outstanding dues of creditors other than micro enterprises and	510.53	467.99	329.61
Other current liabilities	297.03	301.57	48.13
Short-term provisions	-	183.78	-
	1,209.04	991.89	1,287.63
Total	6,880.96	5,145.55	5,488.38
ASSETS			
<i>Non-current assets</i>			
Property, Plant and Equipment			
Tangible assets	1,876.24	1,646.38	1,843.43
Intangible assets	683.28	123.81	251.34
Capital work-in-progress	236.41	137.48	167.21
Deferred tax Assets (net)	11.49	-	7.52
Long-term loans and advances	418.56	292.54	286.99
Non-current Investment	203.48	8.03	153.45
	3,429.46	2,208.24	2,709.94
<i>Current assets</i>			
Current investments	369.78	-	1,379.51
Inventories	340.03	155.77	341.38
Trade receivables	670.33	366.44	599.04
Cash and cash equivalents	1,706.56	1,971.32	176.40
Short-term loans and advances	364.26	364.64	282.11
Other current assets	0.54	79.14	-
	3,451.50	2,937.31	2,778.44
Total	6,880.96	5,145.55	5,488.38

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mahore

Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPH9648



For Vaidya Sane Ayurved Laboratories Ltd

Rohit Sane

Chairman & Managing Director

DIN: 00679851

Place : Thane

Date : 14/11/2023



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Consolidated Statement of profit and loss for the Half year ended 30-Sep-2023

Particulars	(Rupees in lakhs)		
	For the Half Year Ended	For the Half Year Ended	For the Year Ended
	September 30, 2023	September 30, 2022	March 31, 2023
	Unaudited	Unaudited	Audited
Revenue			
Revenue from operations	5,110.05	4,558.72	9,916.89
Other income	63.31	82.51	136.09
Total revenue	5,173.36	4,641.23	10,052.98
Expenses			
Purchases of stock-in-trade	1,493.49	1,306.45	2,762.24
Employee benefit expenses	1,355.83	1,083.80	2,199.93
Finance costs	16.05	11.30	18.75
Depreciation and amortisation expense	158.65	115.53	259.79
Other expenses	1,992.41	1,751.33	4,169.03
Total expenses	5,016.43	4,268.41	9,409.74
Profit / (loss) before prior period adjustments & tax.	156.93	372.82	643.24
Prior period adjustments	-	-	-
Profit / (loss) before	156.93	372.82	643.24
Extraordinary items	-	-	-
Profit / (loss) before tax	156.93	372.82	643.24
Tax expense			
Current tax	39.31	99.30	172.26
Deferred tax (expense)/income	(0.12)	(0.08)	(12.26)
Profit for the year	117.74	273.60	483.24
Profit / (loss) Share of Minority Interest	0.16	(0.27)	(0.05)
Profit / (loss) Share of Owner	117.58	-27.10	483.29
Earnings per equity share			
[Nominal value per share Rs. 10 (PY. 2022-23 - Rs.10)]			
Basic	1.12	2.60	4.60
Diluted	0.93	2.60	4.60

Notes :

- The above financial results for the half year ended September 30, 2023 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th Nov, 2023
- As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid un-audited financial results for the half year ended 30th SEP 2023, which were also approved by the Audit Committee and Board at their meeting held on Tuesday, 14th Nov, 2023.
- The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- As per MCA Notification W/td 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adapted IND-AS for preparation of financial results.
- The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below,

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	1,600	0.00
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1972.98	0.00

6) The losses applicable to the minority in a consolidated subsidiary may exceed the minority interest in the equity of the subsidiary. The excess, and any further losses applicable to the minority, are adjusted against the majority interest except to the extent that the minority has a binding obligation to, and is able to, make good the losses. If the subsidiary subsequently reports profits, all such profits are allocated to the majority interest until the minority's share of losses previously absorbed by the majority has been recovered.

7) During the year company has acquired two private limited company namely Dynamic Remedies Pvt Ltd and UV Ayurgen Pharma Pvt Ltd through share purchase agreement as a result of this investment the said companies have become wholly owned subsidiaries of the Company during the period under Limited Review.

8) Company has issued Share Warrants during the year to promoters and to non promoters during the period under limited review.

As per our report on even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

 Amit Mohare
Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 231486018GWJPH9648

For Vaidya Sane Ayurved Laboratories Ltd

Rohit Sane

Chairman & Managing Director

DIN: 00679851

Place : Thane

Date : 14/11/2023

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

(CIN No. : L73100PN1999PLC013509)

Consolidated Cash flow statement for the half year ended 30-Sep-2023

(Rupees in lakhs)

	Unaudited	Unaudited	Audited
	For the year ended 30-Sep-2023	For the year ended 30-Sep-2022	For the year ended 31-Mar-23
Cash flows from operating activities			
Profit before tax	156.93	372.82	643.24
Adjustments to reconcile net profit to net cash and cash equivalents used in operating activities			
Depreciation and amortisation expense	158.65	115.53	259.79
Profit on sale of Investment	(12.36)	-	-
Finance Cost	16.05	-	18.75
Rent Income	(21.16)	-	(46.55)
Excess provision written back	(7.37)	-	(2.04)
Interest income on bank deposits	(19.87)	(53.24)	(87.27)
Dividend Income	(0.12)	-	(0.05)
Minority Interest	-	-	0.21
	270.75	435.11	786.08
Change in operating assets and liabilities			
(Increase)/Decrease in inventory	1.35	(5.71)	(191.33)
(Increase)/Decrease in accounts receivable	(71.29)	(10.58)	(244.44)
(Increase)/Decrease in other current assets	(210.23)	1,824.19	
Decrease/(Increase) in long term and short term advances	-	(459.06)	(285.99)
(Decrease)/Increase in Other Long Term Liabilities	-	89.12	
(Decrease)/Increase in accounts payable	(378.59)	(269.87)	161.98
(Decrease)/Increase in other current liabilities	(32.58)	(121.63)	32.21
(Decrease)/Increase in Long-term and Short-term provisions	(11.55)	66.74	10.16
	(432.14)	1,548.31	268.67
Cash flow from operations	(42.80)	99.30	(262.26)
Net cash flow from operating activities	(474.94)	1,449.01	6.41
Cash flows from investing activities			
Purchase of tangible/intangible assets	(692.60)	(247.97)	(697.91)
Proceeds from sale of tangible/intangible assets	-	48.65	
Purchase of current investments in shares	(254.28)	481.09	(153.44)
Dividend Income	0.12	-	0.05
Rent received	21.16	-	46.55
Proceeds from maturity of fixed deposit	1,022.49	-	769.34
Interest received	19.33	53.24	87.27
	116.22	335.01	51.86
Net cash used in investing activities			
Cash flows from Investing activities			
Money received against share warrents	1,343.13	-	-
Short Term Loan/(Repayment)	388.08	(67.78)	(92.93)
Long Term Loan Repayment	-	-	-
Interest paid	(16.05)	-	(18.75)
Interim Dividend paid	(26.28)	-	(26.28)
	1,688.88	(67.78)	(137.96)
Cash flows from financing activities			
Net (decrease)/ increase in cash and cash equivalents	1,330.16	1,716.23	(79.69)
Cash and cash equivalents at the beginning of the year	176.40	256.09	256.09
Cash and cash equivalents at the end of the year	1,506.56	1,972.32	176.40
Cash and cash equivalents comprise of			
Cash on hand	21.41	11.08	17.94
Balances with banks in current accounts	1,485.15	1,961.24	158.46
Total	1,506.56	1,972.32	176.40

As per our report of even date attached.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mohare

Partner

Membership No. 148601

Place : Thane

Date : 14/11/2023

UDIN : 23148601BGWJPH9648

For Vaidya Sane Ayurved Laboratories Ltd

Rohit Sane

Chairman & Managing Director

DIN: 00679851

Place : Thane

Date : 14/11/2023